Table SVII. *Post hoc* **analysis using an updated risk set sampling where the case and control group included only those patients without actinic keratosis before the index date**

	OR (95% CI)[f]	*p*-value
No adjustment	1.38 (1.07–1.78)	0.014
Comorbidities		
Alcohol-associated comorbidity	1.37 (1.06–1.78)	0.015
Crohn's disease	1.38 (1.07–1.78)	0.014
Diabetes	1.38 (1.07–1.79)	0.014
Liver disease	1.38 (1.07–1.78)	0.014
Peptic ulcer (gastric and duodenal ulcer)	1.38 (1.07–1.78)	0.014
Smoking-associated conditions	1.38 (1.07–1.78)	0.013
Kidney-associated disease	1.38 (1.07–1.78)	0.013
Rheumatoid arthritis	1.39 (1.07–1.81)	0.014
Psoriatic arthritis	1.44 (1.08–1.91)	0.013
Drugs		
Acitretin	1.35 (1.04–1.75)	0.023
Ciclosporin	1.34 (1.03–1.74)	0.029
Azathioprine	1.37 (1.06–1.77)	0.016
Tumour necrosis factor α inhibitor	1.26 (0.96–1.66)	0.097
Interleukin pathway-inhibitor	1.39 (1.07–1.79)	0.013
Immunosuppressants excluding MTX[a]	1.15 (0.87–1.52)	0.32
Other variables		
CCI index[b]	1.37 (1.06–1.78)	0.016
Civic status[c]	1.38 (1.06–1.78)	0.015
Education[d]	1.38 (1.07–1.79)	0.014
Income[e]	1.38 (1.07–1.79)	0.013

The different drugs were defined as ever-exposure implying ≥1 filled prescription(s) of the respective drug/drug class.
[a]Immunosuppressive drugs other than methotrexate (MTX) were defined as a drug starting with Anatomical Therapeutic Chemical (ATC) code starting with L04A other than L04AX03 (i.e. the ATC-code for MTX). [b]Charlson comorbidity index (CCI) 0 indicates no comorbidity; CCI 1, mild comorbidity; CCI 2+, moderate to severe comorbidity. [c]Civic status: married, unmarried or missing data. [d]Educational levels: low, compulsory school (<10 years); middle, upper secondary school (10–12 years); high, higher education (>12 years). [e]Income quartiles derive from the original psoriasis cohort consisting of 81,738 patients. [f]Odds ratios (ORs) represent ever-use of MTX associated with cutaneous squamous cell carcinoma (cSCC) individually adjusted for each potential confounder.
CI: confidence interval.